Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CASP6 | P55212 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17686382 | 0.81 | KDM4E (0.37) | L3MBTL1KDM4EGAA | |
| SCHEMBL2244928 | 0.68 | THRB (0.35) | THRBATML3MBTL1CASP6KDM4E | |
| SCHEMBL2241744 | 0.68 | THRB (0.35) | THRBATML3MBTL1CASP6KDM4E | |
| SCHEMBL28527648 | 0.67 | CYP3A4 (0.32) | — | |
| SCHEMBL28525796 | 0.67 | CYP3A4 (0.32) | — | |
| SCHEMBL2239739 | 0.64 | MEN1 (0.38) | THRBATML3MBTL1CASP6KDM4E | |
| SCHEMBL12353791 | 0.62 | MGAM (0.39) | THRBATML3MBTL1CASP6GAA | |
| SCHEMBL17872979 | 0.62 | MGAM (0.39) | THRBATML3MBTL1CASP6GAA | |
| SCHEMBL21997173 | 0.62 | GAA (0.35) | L3MBTL1GAATSHRPOLB | |
| SCHEMBL9774617 | 0.62 | THRB (0.69) | THRBATML3MBTL1CASP6KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190278-A1 | BICYCLIC HETEROCYCLIC DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO. | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190278-A1 | BICYCLIC HETEROCYCLIC DERIVATIVE | REN, AGTR1, AGTR2 | THRB 456/4885ATM 4606/4885L3MBTL1 3310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.